Immunoglobulin G Replacement Therapy: Particularities of a Portuguese Cohort
DOI:
https://doi.org/10.20344/amp.20677Keywords:
Immunoglobulin G/therapeutic useAbstract
N/a.
Downloads
References
Krivan G, Jolles S, Granados EL, Paolantonacci P, Ouaja R, Cissé OA, et al. New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients. Am J Clin Exp Immunol. 2017;6:76-83.
Cherin P, Marie I, Michallet M, Pelus E, Dantal J, Crave JC, et al. Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence. Autoimmun Rev. 2016;15:71-81. DOI: https://doi.org/10.1016/j.autrev.2015.09.002
Jolles S, Orange JS, Gardulf A, Stein MR, Shapiro R, Borte M, et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol. 2015;179:146-60. DOI: https://doi.org/10.1111/cei.12485
Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20:94-100. DOI: https://doi.org/10.1023/A:1006678312925
Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125:1354-60.e4. DOI: https://doi.org/10.1016/j.jaci.2010.02.040
Kittner JM, Grimbacher B, Wulff W, Jager B, Schmidt RE. Patients’ attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol. 2006;26:400-5. DOI: https://doi.org/10.1007/s10875-006-9031-5
Pulvirenti F, Cinetto F, Pecoraro A, Carrabba M, Crescenzi L, Neri R, et al. Health-related quality of life in patients with covid under different schedules of immunoglobulin administration: prospective multicenter study. J Clin Immunol. 2019;39:159-70. DOI: https://doi.org/10.1007/s10875-019-0592-5
Anterasian C, Duong R, Gruenemeier P, Ernst C, Kitsen J, Geng B. Quality of life differences for primary immunodeficiency patients on home SCIG versus IVIG. J Clin Immunol. 2019;39:814-22. DOI: https://doi.org/10.1007/s10875-019-00705-5
Overton PM, Shalet N, Somers F, Allen JA. Patient preferences for subcutaneous versus intravenous administration of treatment for chronic immune system disorders: a systematic review. Patient Prefer Adher. 2021;19:811-34. DOI: https://doi.org/10.2147/PPA.S303279
Espanol T, Prevot J, Drabwell J, Sondhi S, Olding L. Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment. Patient Prefer Adher. 2014;2:621-9. DOI: https://doi.org/10.2147/PPA.S60771
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
